Laboratoire OBO, France – 21 March 2022 A new CE-IVD marked test, the OSANTYS SARS-CoV-2 Duo RT-qPCR kit, allows for rapid (without extraction) and standardised detection of Sars-Cov-2 from a simple cell lysate, regardless of the type of sample (nasopharyngeal, oropharyngeal or saliva).
Laboratoire OBO, France – 04 February 2022 The ongoing development of a high-risk human papillomavirus (HPV) detection test using real-time PCR with partial genotyping. This kit will allow for the individualised identification of 3 genotypes associated with the highest carcinogenic potential, namely HPV16, HPV18 and HPV45, and 2 groups simultaneously 45, 31, 33, 52, 58 […]
Laboratoire OBO, France – 06 December 2021 Laboratoire OBO is attending the RICAI conference to present its 1st marketed test in the fight against the Covid-19. We will be represented by the company R-Biopharm, who can tell you all about us. You will also be able to consult our roll-up banner describing the advantages of […]
Laboratoire OBO, France – 28 June 2021 1st CE-IVD marked SARS-CoV-2 detection test for Laboratoire OBO following its validation by the CNR. In its commitment to fight the COVID-19 pandemic, Laboratoire OBO was able to produce its first RT-qPCR test in record time. The CE-marked OSANTYS SARS-CoV-2 RT-qPCR test kit can be applied to three […]
Laboratoire OBO, France – 17 June 2021 The CNR has validated the 1st RT-qPCR test that can detect SARS-CoV-2 launched under the OSANTYS brand, a trademark of Laboratoire OBO. The evaluation of the analytical performance for detecting SARS-CoV-2 in comparison with the CNR IPP reference technique has provided very encouraging results for the company’s first […]